- Company
- SGLT-2 inhibitor Jardiance to expand HF indication
- by Eo, Yun-Ho Mar 15, 2021 06:28am
- Following after Forxiga, Jardiance is also preparing to introduce the heart failure indication in South Korea. According to a pharmaceutical industry insider, Boehringer Ingelheim Korea is waiting for the health authority’s review result in its sodium-glucose cotransporter 2 (SGLT-2) inhibitor Jardiance’ request to expand indication in
- Company
- HER2 targeted therapy market exceeds KRW 200 billion
- by An, Kyung-Jin Mar 15, 2021 06:28am
- The South Korean market for targeted therapy prescribed to treat human epidermal growth factor receptor 2 (HER2)-positive breast cancer has exceeded 200 billion won in sales last year. Two domestically developed biosimilars increased the market influence and made up for the sale revenue void in the original by the original maker’s follow-on dru
- Company
- 3 companies have abandoned Pelubi's patent challenge
- by Kim, Jin-Gu Mar 12, 2021 06:22am
- Pharmaceutical companies that were trying to overcome the patent of Daewon's anti-inflammatory pain reliever Pelubi (Pelubiprofen) gave up. After Mother's and Hutecs voluntarily withdrew the request for a referee last year, Nexpharm was recently added, leaving only three of the six challengers. Some of the companies that voluntarily withdre
- Company
- Genuone is licensed to manufacture Pariet
- by Kim, Jin-Gu Mar 11, 2021 06:07am
- Genuone received permission to change the manufacturer of Pariet (Rabeprazole) with an annual prescription amount of &8361;15 billion. This is the first achievement since its independence from Kolmar Korea and officially launched earlier this year. Genuone announced on the 9th that it has received permission to change the manufacturer of
- Company
- Tecentriq as liver cancer first-line treatment green lit
- by Mar 11, 2021 06:07am
- The South Korean health authority is seemingly giving a green light to an immunotherapy Tecentriq for its combination therapy as a first-line treatment in liver cancer. A pharmaceutical industry source reported on Mar. 9 that the Health Insurance Review and Assessment Service (HIRA) Cancer Deliberation Committee approved of the clinical e
- Company
- Sales of erectile dysfunction generic drugs are increasing
- by An, Kyung-Jin Mar 11, 2021 06:06am
- Sales of the domestic erectile dysfunction treatment market decreased due to COVID-19. Sales declined, mainly for large items in the early days of the COVID-19 spread, and recovered after the second half of the year. Although sales of major products were low, generic products sold by Korean companies such as Hanmi and Chong Kun Dang were launche
- Company
- Chong Kun Dang applied for COVID-19 treatment
- by An, Kyung-Jin Mar 10, 2021 06:27am
- Chong Kun Dang announced on the 8th that it has applied to the MFDS for approval of the conditional marketing authorization (CMA) and phase 3 clinical trial plan of Nafabelltan (Nafamostat) as a treatment for COVID-19 for patients with severe and high risk. Nafabelltan is a drug used as a therapeutic agent for acute pancreatitis and as an
- Company
- First CAR-T treatment Kymriah was approved in Korea
- by Eo, Yun-Ho Mar 9, 2021 06:24am
- The first CAR-T treatment drug Kymriah was approved in Korea. The MFDS announced on the 5th that it has approved the world's first chimeric antigen receptor T cell (CAR-T) treatment Kymriah (Tisagenlecleucel), which was applied for approval by Novartis Korea, as the first advanced biopharmaceutical under the Advanced Renewable Bio Act.
- Company
- Antihypertension Zofenil and Adalat Oros to halt supply
- by Mar 9, 2021 06:24am
- Zofenil (zofenopril calcium) tablet and Adalat Oros (nifedipine) 60 mg tablet that had shortage issues are ultimately ceasing the supply. On Mar. 5, pharmaceutical distribution industry source reported Menarini Korea has informed of halting the supply of an antihypertension drug Zofenil in 7.5 mg, 15 mg and 30 mg doses. Menarini Kore
- Company
- Mercilon's sales fell 16%
- by Kim, Jin-Gu Mar 8, 2021 06:20am
- The OTC oral contraceptives market is fluctuating. Sales of Mercilon and MYVLAR, the existing No. 1 and 2 items, declined significantly for each reason. Sales of new products such as Senseday and Daon succeeded in establishing a very stable market. The cause of the change in the market is the change of vendor and the launch of new produc
